These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 9331523)
21. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Napolitano A; Del Dotto P; Petrozzi L; Dell'Agnello G; Bellini G; Gambaccini G; Bonuccelli U Clin Neuropharmacol; 1999; 22(1):24-9. PubMed ID: 10047930 [TBL] [Abstract][Full Text] [Related]
22. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690 [TBL] [Abstract][Full Text] [Related]
23. [Cabergoline in the treatment of Parkinson's disease]. Pastor P; Tolosa E Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865 [TBL] [Abstract][Full Text] [Related]
24. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Linazasoro G; Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487 [TBL] [Abstract][Full Text] [Related]
25. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of high-dose cabergoline in Parkinson's disease. Odin P; Oehlwein C; Storch A; Polzer U; Werner G; Renner R; Shing M; Ludolph A; Schüler P Acta Neurol Scand; 2006 Jan; 113(1):18-24. PubMed ID: 16367894 [TBL] [Abstract][Full Text] [Related]
27. IPX066 , a mixed immediate/sustained-release levodopa preparation for Parkinson's disease. Ondo W Expert Opin Pharmacother; 2014 Oct; 15(14):2081-5. PubMed ID: 25146967 [TBL] [Abstract][Full Text] [Related]
31. Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study. Utsumi H; Acta Med Okayama; 2012; 66(2):163-70. PubMed ID: 22525474 [TBL] [Abstract][Full Text] [Related]
32. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Högl B; Rothdach A; Wetter TC; Trenkwalder C Neuropsychopharmacology; 2003 Oct; 28(10):1866-70. PubMed ID: 12865895 [TBL] [Abstract][Full Text] [Related]
33. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. LeWitt PA Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210 [TBL] [Abstract][Full Text] [Related]
34. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. Romigi A; Stanzione P; Marciani MG; Izzi F; Placidi F; Cervellino A; Giacomini P; Brusa L; Grossi K; Pierantozzi M J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238 [TBL] [Abstract][Full Text] [Related]
35. Cabergoline : a review of its use in the treatment of Parkinson's disease. Curran MP; Perry CM Drugs; 2004; 64(18):2125-41. PubMed ID: 15341508 [TBL] [Abstract][Full Text] [Related]
36. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Marco AD; Appiah-Kubi LS; Chaudhuri KR Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694 [TBL] [Abstract][Full Text] [Related]
37. Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010. Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Yamamoto M; Nakayama T PLoS One; 2014; 9(6):e99021. PubMed ID: 24906013 [TBL] [Abstract][Full Text] [Related]
38. The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients. Brusa L; Pavino V; Massimetti MC; Bove R; Iani C; Stanzione P Funct Neurol; 2013; 28(1):13-7. PubMed ID: 23731911 [TBL] [Abstract][Full Text] [Related]